ReviewNature reviews. Neurology2016
The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative.
Review in Nature reviews. Neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03586986 (Risk Factors in Early Multiple Sclerosis), which is not on this map. Cited by 194 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Risk Factors in Early Multiple Sclerosis
Who cites it
194 citing papers in PubMed, 7 syntheses or guidelines pooled it, 392 citations in OpenAlex.
- Expert Panel Consensus Guidelines of the German Society of Neuroradiology on the Use of Magnetic Resonance Imaging in the Diagnosis and Monitoring of Multiple Sclerosis.Clinical neuroradiology · 2026Guideline
- Central vein sign and paramagnetic rim lesions in pediatric-onset multiple sclerosis: a systematic review and meta-analysis.Journal of neurology · 2026Pooled it
- Accuracy of the central vein sign in diagnosis of multiple sclerosis: a systematic review and meta-analysis.Journal of neurology · 2026Pooled it
- Prevalence and epidemiology of stroke in patients with multiple sclerosis: a systematic review and meta-analysis.Journal of neurology · 2024Pooled it
- Quantitative susceptibility mapping in multiple sclerosis: A systematic review and meta-analysis.NeuroImage. Clinical · 2024Pooled it
- The etiology and evolution of magnetic resonance imaging-visible perivascular spaces: Systematic review and meta-analysis.Frontiers in neuroscience · 2023Pooled it
- The "Central Vein Sign" on T2*-weighted Images as a Diagnostic Tool in Multiple Sclerosis: A Systematic Review and Meta-analysis using Individual Patient Data.Scientific reports · 2019Pooled it
- Central Vein Sign Profile of Newly Developing Lesions in Multiple Sclerosis: A 3-Year Longitudinal Study.Neurology(R) neuroimmunology & neuroinflammation · 2022Trial
- Fast Submillimeter Whole-Brain TMagnetic resonance in medicine · 2026Article
- Simultaneous TMagnetic resonance in medicine · 2026Article
- Use of MRI in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease - MAGNIMS consensus recommendations.Nature reviews. Neurology · 2026Review
- Application of the 2024 McDonald Criteria: Earlier Diagnosis and Avoiding Misdiagnosis of Multiple Sclerosis in a Global Setting.Neurology · 2026Review
- Challenges and future directions for multiple sclerosis after the 2024 McDonald diagnostic criteria.Nature medicine · 2026Article
- AI-Powered Gradient Echo Plural Contrast Imaging (AI-GEPCI)-A Comprehensive Neurological Protocol From a Single MRI Scan.Journal of magnetic resonance imaging : JMRI · 2026Article
- Application of the 2024 McDonald Criteria in Individuals With Nonspecific Symptoms or Incidental Imaging Findings in a Multicenter Study.Neurology · 2026Observational
- Beyond dissemination criteria: lesion-based longitudinal MRI of atypical demyelinating lesions at the boundary of multiple sclerosis.Journal of neurology · 2026Article
- Tract-based χ-separation imaging differentiates multiple sclerosis from neuromyelitis optica spectrum disorder by mapping iron and myelin signatures.BMC medical imaging · 2026Article
- Complex Deep Neural Networks for Denoising Ultra-Fast Submillimeter T2*-weighted Imaging and Quantitative Susceptibility Mapping.European journal of radiology artificial intelligence · 2026Article
- Pathological signatures of white matter lesions in multiple sclerosis versus stroke: a synthetic MRI study.Neuroradiology · 2026Article
- Central Vein Sign and Paramagnetic Rim Lesions in Patients with Relapsing-Remitting Multiple Sclerosis: An Assessment of Prevalence and Anatomical Location.Neurology international · 2026Article
134 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 13 institutions in 5 countries.
Funding
Abstract
Over the past few years, MRI has become an indispensable tool for diagnosing multiple sclerosis (MS). However, the current MRI criteria for MS diagnosis have imperfect sensitivity and specificity. The central vein sign (CVS) has recently been proposed as a novel MRI biomarker to improve the accuracy and speed of MS diagnosis. Evidence indicates that the presence of the CVS in individual lesions can accurately differentiate MS from other diseases that mimic this condition. However, the predictive value of the CVS for the development of clinical MS in patients with suspected demyelinating disease is still unknown. Moreover, the lack of standardization for the definition and imaging of the CVS currently limits its clinical implementation and validation. On the basis of a thorough review of the existing literature on the CVS and the consensus opinion of the members of the North American Imaging in Multiple Sclerosis (NAIMS) Cooperative, this article provides statements and recommendations aimed at helping radiologists and neurologists to better understand, refine, standardize and evaluate the CVS in the diagnosis of MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.